Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (R)-Flecainide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | KCNA5 | P22460 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | CACNA1D | Q01668 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | CACNA1S | Q13698 | 1/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.93 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.93 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flecainide SCHEMBL17799127 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP2D6LMNACYP2C9CYP3A4 | |
| Flecainide SCHEMBL29385957 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP2D6LMNACYP2C9CYP3A4 | |
| Flecainide SCHEMBL14970 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP2D6LMNACYP2C9CYP3A4 | |
| Flecainide SCHEMBL5569654 | 0.99 | CYP1A2 (0.98) | CYP1A2CYP2D6LMNACYP2C9CYP3A4 | |
| Flecainide SCHEMBL5569649 | 0.99 | CYP1A2 (0.98) | CYP1A2CYP2D6LMNACYP2C9CYP3A4 | |
| Flecainide SCHEMBL308966 | 0.96 | SMN1; SMN2 (1.00) | CYP1A2CYP2D6LMNACYP2C9CYP3A4 | |
| Flecainide SCHEMBL9614368 | 0.96 | SMN1; SMN2 (1.00) | CYP1A2CYP2D6LMNACYP2C9CYP3A4 | |
| Flecainide SCHEMBL121583 | 0.96 | SMN1; SMN2 (1.00) | CYP1A2CYP2D6LMNACYP2C9CYP3A4 | |
| SCHEMBL20921172 | 0.94 | CYP1A2 (0.89) | CYP1A2CYP2D6LMNACYP2C9CYP3A4 | |
| SCHEMBL19822359 | 0.94 | CYP1A2 (0.89) | CYP1A2CYP2D6LMNACYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 12262 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102339-A1 | ARTIFICIAL INTELLIGENCE-BASED METHOD AND SYSTEM FOR RAPID DRUG SCREENING USING INTRACELLULAR ELECTRICAL RECORDINGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-15 | — | — | WO | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-12576074-B2 | Kits and methods for induction of cardioversion in subjects with atrial arrhythmias | INCARDA THERAPEUTICS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| US-12576073-B2 | Antiarrhythmic formulation | INCARDA THERAPEUTICS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| US-20260061000-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS, INCLUDING ATRIAL FIBRILLATION | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2026-03-05 | — | — | US | claimed |
| EP-4691556-A2 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF | H. Lundbeck A/S (DK) | 2026-02-11 | — | — | EP | claimed |
| US-12529704-B2 | Methods for objective assessment of stress, early detection of risk for stress disorders, matching individuals with treatments, monitoring response to treatment, and new methods of use for drugs | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2026-01-20 | — | — | US | claimed |
| EP-4674894-A2 | COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES | Hemoteq AG (DE) | 2026-01-07 | — | — | EP | claimed |
| US-20250387389-A1 | METHODS OF TREATING DISEASE WITH LEVOKETOCONAZOLE | XERIS PHARMACEUTICALS, INC. (US) | 2025-12-25 | — | — | US | claimed |
| US-5336622-A | Competitive binding using a fluorescent dye tracer; monitoring dosage in biological fluid; sensitivity; accuracy; efficiency | ABBOTT LABORATORIES (US) | 1994-08-09 | — | — | US | claimed |
| EP-0242847-B1 | TRACERS FOR USE IN FLECAINIDE FLUORESCENCE POLARIZATION IMMUNOASSAY | ABBOTT LABORATORIES (US) | 1993-06-02 | — | — | EP | claimed |
| EP-0371683-B1 | CONTROLLED RELEASE FLECAINIDE ACETATE FORMULATION | RIKER LABORATORIES, INC. (US) | 1993-04-21 | — | — | EP | claimed |
| US-4962095-A | Method of reducing pre-and post-ischemic myocardial arrhythmias and fibrillation | E. R. SQUIBB & SONS, INC. (US) | 1990-10-09 | — | — | US | claimed |
| EP-0383258-A2 | Pharmaceutical compositions for reducing pre and post-ischemic myocardial arrhythmias and fibrillation | E.R. SQUIBB & SONS, INC. (US) | 1990-08-22 | — | — | EP | claimed |
| US-4938966-A | Controlled release flecainide acetate formulation | RIKER LABORATORIES, INC. (US) | 1990-07-03 | — | — | US | claimed |
| EP-0371683-A1 | Controlled release flecainide acetate formulation | RIKER LABORATORIES, INC. (US) | 1990-06-06 | — | — | EP | claimed |
| US-4931464-A | ADMINISTERING ZOFENOPRIL OR ITS SALT | E. R. SQUIBB & SONS, INC. (US) | 1990-06-05 | — | — | US | claimed |
| EP-0242847-A2 | Tracers for use in flecainide fluorescence polarization immunoassay | ABBOTT LABORATORIES (US) | 1987-10-28 | — | — | EP | claimed |
| US-4675448-A | Chlorination process | ETHYL CORPORATION (US) | 1987-06-23 | — | — | US | claimed |